Key facts
- This page summarizes BAKER BROS. ADVISORS LP's Form 4 filing for INCYTE CORP (INCY).
- 4 reported transactions and 12 derivative rows are listed below.
- Accepted by SEC: 11 May 2026, 16:45.
BAKER BROS. ADVISORS LP - 08 May 2026 Form 4 Insider Report for INCYTE CORP (INCY)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- INCY
- Reported as of
- 08 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 May 2026, 16:45:25 UTC
- Prior SEC filing
- 22 Apr 2026
- Next SEC filing
- 22 May 2026
- Source filing
- View source filing
- Reporting owner signature
- By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
BAKER BROS. ADVISORS LP filed Form 4 for INCYTE CORP (INCY) on 11 May 2026.
Change
- Previous filing in this sequence was filed on 22 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (6)
CIK 0001263508
Primary reporting owner
BAKER BROS. ADVISORS LP
- Relationship
- Director, 10%+ Owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
- Signature date
- 11 May 2026
CIK 0001551139
667, L.P.
- Relationship
- Director, 10%+ Owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
- Signature date
- 11 May 2026
CIK 0001580575
Baker Bros. Advisors (GP) LLC
- Relationship
- Director, 10%+ Owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- /s/ Julian C. Baker
- Signature date
- 11 May 2026
CIK 0001363364
Baker Brothers Life Sciences LP
- Relationship
- Director, 10%+ Owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
- Signature date
- 11 May 2026
CIK 0001087940
BAKER FELIX
- Relationship
- Director, 10%+ Owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P., /s/ Name: Scott L. Lessing, Title: President
- Signature date
- 11 May 2026
CIK 0001087939
BAKER JULIAN
- Relationship
- Director, 10%+ Owner
- Address
- 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
- Signature
- /s/ Felix J. Baker
- Signature date
- 11 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INCY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +15,000
- Change %
- +0.53%
- Price
- $84.53*
- Shares after
- 2,833,039
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3, F4, F5, F6, F7
INCY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +15,000
- Change %
- +0.53%
- Price
- $84.53*
- Shares after
- 2,833,039
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3, F4, F5, F6, F7
INCY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +15,000
- Change %
- +0.53%
- Price
- $84.53*
- Shares after
- 2,833,039
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3, F4, F5, F6, F7
INCY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +15,000
- Change %
- +0.53%
- Price
- $84.53*
- Shares after
- 2,833,039
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3, F4, F5, F6, F7
INCY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +15,000
- Change %
- +0.53%
- Price
- $84.53*
- Shares after
- 2,833,039
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3, F4, F5, F6, F7
INCY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +15,000
- Change %
- +0.53%
- Price
- $84.53*
- Shares after
- 2,833,039
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F3, F4, F5, F6, F7
INCY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +15,000
- Change %
- +0.05%
- Price
- $84.53*
- Shares after
- 28,203,718
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3, F4, F5, F6, F7, F8
INCY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +15,000
- Change %
- +0.05%
- Price
- $84.53*
- Shares after
- 28,203,718
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3, F4, F5, F6, F7, F8
INCY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +15,000
- Change %
- +0.05%
- Price
- $84.53*
- Shares after
- 28,203,718
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3, F4, F5, F6, F7, F8
INCY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +15,000
- Change %
- +0.05%
- Price
- $84.53*
- Shares after
- 28,203,718
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3, F4, F5, F6, F7, F8
INCY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +15,000
- Change %
- +0.05%
- Price
- $84.53*
- Shares after
- 28,203,718
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3, F4, F5, F6, F7, F8
INCY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +15,000
- Change %
- +0.05%
- Price
- $84.53*
- Shares after
- 28,203,718
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3, F4, F5, F6, F7, F8
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 278,773
- Date
- 08 May 2026
- Ownership
- Direct
- Footnotes
- F9
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 278,773
- Date
- 08 May 2026
- Ownership
- Direct
- Footnotes
- F9
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 278,773
- Date
- 08 May 2026
- Ownership
- Direct
- Footnotes
- F9
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 278,773
- Date
- 08 May 2026
- Ownership
- Direct
- Footnotes
- F9
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 278,773
- Date
- 08 May 2026
- Ownership
- Direct
- Footnotes
- F9
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 278,773
- Date
- 08 May 2026
- Ownership
- Direct
- Footnotes
- F9
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 281,190
- Date
- 08 May 2026
- Ownership
- Direct
- Footnotes
- F10
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 281,190
- Date
- 08 May 2026
- Ownership
- Direct
- Footnotes
- F10
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 281,190
- Date
- 08 May 2026
- Ownership
- Direct
- Footnotes
- F10
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 281,190
- Date
- 08 May 2026
- Ownership
- Direct
- Footnotes
- F10
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 281,190
- Date
- 08 May 2026
- Ownership
- Direct
- Footnotes
- F10
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 281,190
- Date
- 08 May 2026
- Ownership
- Direct
- Footnotes
- F10
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,410
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F11
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,410
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F11
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,410
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F11
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,410
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F11
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,410
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F11
INCY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,410
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Footnotes
- F11
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INCY
transaction
Derivative
Non-Qualified Stock Options
Options Exercise
- Transaction value
- Shares
- -15,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $84.53
- Footnotes
- F1, F2, F3, F4, F6, F7
INCY
transaction
Derivative
Non-Qualified Stock Options
Options Exercise
- Transaction value
- Shares
- -15,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $84.53
- Footnotes
- F1, F2, F3, F4, F6, F7
INCY
transaction
Derivative
Non-Qualified Stock Options
Options Exercise
- Transaction value
- Shares
- -15,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $84.53
- Footnotes
- F1, F2, F3, F4, F6, F7
INCY
transaction
Derivative
Non-Qualified Stock Options
Options Exercise
- Transaction value
- Shares
- -15,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $84.53
- Footnotes
- F1, F2, F3, F4, F6, F7
INCY
transaction
Derivative
Non-Qualified Stock Options
Options Exercise
- Transaction value
- Shares
- -15,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $84.53
- Footnotes
- F1, F2, F3, F4, F6, F7
INCY
transaction
Derivative
Non-Qualified Stock Options
Options Exercise
- Transaction value
- Shares
- -15,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $84.53
- Footnotes
- F1, F2, F3, F4, F6, F7
INCY
transaction
Derivative
Non-Qualified Stock Options
Options Exercise
- Transaction value
- Shares
- -15,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $84.53
- Footnotes
- F1, F3, F4, F6, F7, F8
INCY
transaction
Derivative
Non-Qualified Stock Options
Options Exercise
- Transaction value
- Shares
- -15,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $84.53
- Footnotes
- F1, F3, F4, F6, F7, F8
INCY
transaction
Derivative
Non-Qualified Stock Options
Options Exercise
- Transaction value
- Shares
- -15,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $84.53
- Footnotes
- F1, F3, F4, F6, F7, F8
INCY
transaction
Derivative
Non-Qualified Stock Options
Options Exercise
- Transaction value
- Shares
- -15,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $84.53
- Footnotes
- F1, F3, F4, F6, F7, F8
INCY
transaction
Derivative
Non-Qualified Stock Options
Options Exercise
- Transaction value
- Shares
- -15,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $84.53
- Footnotes
- F1, F3, F4, F6, F7, F8
INCY
transaction
Derivative
Non-Qualified Stock Options
Options Exercise
- Transaction value
- Shares
- -15,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 08 May 2026
- Ownership
- See Footnotes
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $84.53
- Footnotes
- F1, F3, F4, F6, F7, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 11 footnotes
Footnote F1
Common Stock ("Common Stock") of Incyte Corporation (the "Issuer") received upon exercise of 15,000 non-qualified stock options to purchase Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer. Julian C. Baker, pursuant to the policies of the Adviser, does not have any right to the pecuniary interest in the Stock Options issued for his service on the board of directors of the Issuer (the "Board") or the Common Stock received upon exercise of such Stock Options. Each of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons owns an indirect proportionate pecuniary interest in the Common Stock received upon exercise of the Stock Options issued in connection with Julian C. Baker's service on the Board less the exercise cost of those Stock Options.
Footnote F2
After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 5 of Table I and in column 9 of Table II directly held by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
Footnote F3
Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
Footnote F4
Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
Footnote F5
Includes beneficial ownership of 15,105 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 12,204 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an "RSU"), 2,518 shares of Common Stock underlying unvested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 Stock Options that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.
Footnote F6
Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.
Footnote F7
Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
Footnote F8
After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 5 of Table I and in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
Footnote F9
Common Stock directly held by Julian C. Baker, a managing member of the Adviser GP.
Footnote F10
Common Stock directly held by Felix J. Baker, a managing member of the Adviser GP.
Footnote F11
Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in 33,410 shares of Common Stock directly held by FBB Associates. Julian C. Baker and Felix J. Baker are the sole partners of FBB Associates. Julian C. Baker and Felix J. Baker disclaim beneficial ownership of the securities held directly by FBB Associates except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Julian C. Baker or Felix J. Baker is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
SEC remarks
Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC, the sole general partner of Baker Bros. Advisors LP, is a director of Incyte Corporation (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Julian C. Baker are deemed directors by deputization of the Issuer.